Unicycive Therapeutics Inc
Unicycive Therapeutics Inc is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of neurological and psychiatric disorders.
Business. Unicycive Therapeutics Inc (UNCY.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Unicycive Therapeutics Inc (UNCY.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Unicycive Therapeutics Inc has a market capitalization of $219.74 million and a price-to-book ratio of 7.28, indicating that the market is valuing the company at a premium to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. The current ratio of 2.59 indicates that the company has sufficient current assets to cover its current liabilities.
The company's profitability metrics are negative, with a return on equity of -87.94% and a return on assets of -54.04%. These figures indicate that the company is not generating returns for its shareholders and is underperforming in terms of asset utilization. The operating income and net income are both negative, at -$29.52 million and -$26.56 million, respectively, highlighting the company's current financial challenges.
Unicycive Therapeutics Inc's revenue concentration and geographic exposure are not explicitly detailed in the available data. However, the company's operations are primarily focused on the development and commercialization of therapies for neurological and psychiatric disorders, which may involve a diverse set of markets and customer segments. The lack of detailed segment data limits the ability to assess specific revenue concentrations.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow is negative at -$31.32 million, and the free cash flow is also negative at -$26.55 million, indicating that the company is not generating positive cash flows from its operations. The capital expenditure is relatively low at -$24,000, suggesting minimal investment in new assets.
The risk assessment for Unicycive Therapeutics Inc indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and the custom valuations do not show any significant adjustments that would indicate a high risk of dilution.
Recent events and filings for Unicycive Therapeutics Inc do not show any significant developments that would impact the company's financial position or strategic direction. The company's analyst estimates suggest a wide range of price targets, with a mean of $38.88 and a median of $31.00, indicating a high level of uncertainty among analysts regarding the company's future performance.
- Unicycive Therapeutics Inc has a high price-to-book ratio of 7.28, indicating that the market is valuing the company at a premium to its book value.
- The company is not generating returns for its shareholders, with a return on equity of -87.94% and a return on assets of -54.04%.
- The company's operating income and net income are both negative, at -$29.52 million and -$26.56 million, respectively.
- The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure.
- The company's liquidity and dilution risks are low, with no immediate filing-based liquidity or dilution flags detected.
- Analyst estimates for Unicycive Therapeutics Inc show a wide range of price targets, with a mean of $38.88 and a median of $31.00.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,57 |
| Revenue | —no estimate | —no estimate | 56,0M USD |
| Operating income | —no estimate | —no estimate | 4,0M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Restricted Stock Units → Common StockAcquired 84 200grant · 2026-05-14
- CFO · Restricted Stock Unit → Common StockAcquired 169 500grant · 2026-05-14
- EVP, Pharmaceuticals and BD · Restricted Stock Unit → Common StockAcquired 169 500grant · 2026-05-14
- EVP, Corporate Strategy · Restricted Stock Units → Common StockAcquired 169 500grant · 2026-05-14
- Director, CEO · Restricted Stock Units → Common StockAcquired 762 200grant · 2026-05-14
- Director · Restricted Stock Units → Common StockAcquired 84 200grant · 2026-05-14
- Director · Restricted Stock Units → Common StockAcquired 42 100grant · 2026-05-14
- Director · Restricted Stock Units → Common StockAcquired 42 100grant · 2026-05-14
- Director · Series A-2 Prime Preferred Stock → Common StockDisposed 652 900 @ $4,90disposition · 2025-08-25
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Return On Equitynet_income / total_equity
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Unicycive Therapeutics Inc Market data — financials · 2026-05-29
- Unicycive Therapeutics Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
- Director · Common StockOther 652 900 · 2025-08-25
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on assets (FY 2025-12-31): -54.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 8.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.63xDerived (calculated)
- Current ratio (FY 2025-12-31): 2.59xDerived (calculated)
- Return on equity (FY 2025-12-31): -87.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -9.6%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -54.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 27.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 70.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 70.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 306.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 11.7%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -66.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 55.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -21.9%Derived (calculated)
- Net income (annual): USD -26.55MSEC XBRL filing
- Cash & equivalents (annual): USD 29.2MSEC XBRL filing
- Shareholders' equity (annual): USD 30.2MSEC XBRL filing
- Operating income (annual): USD -29.52MSEC XBRL filing
- Capex (annual): USD 24KSEC XBRL filing
- Current assets (annual): USD 48.96MSEC XBRL filing
- Total liabilities (annual): USD 18.94MSEC XBRL filing
- Total operating expenses (annual): USD 29.52MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing